ACC.22 Scientific Sessions 2022
News from ACC.22 – New insights from ORION-10 and ORION-11: inclisiran effective in post-MI patients
Inclisiran was effective in lowering LDL cholesterol and generally well tolerated in patients with a prior myocardial infarction (MI), irrespective of the timing of MI, according to latest data from the ORION-10 and ORION-11 studies. Inclisiran is a small interfering ribonucleic acid (siRNA) therapeutic targeting…
read more »
News from ACC.22 late breaking trials: Results from the APOLLO trial with new RNA therapeutic
Results from the APOLLO trial showed that single doses of SLN360, an investigational short interfering RNA (siRNA), resulted in dose-dependent lowering of plasma lipoprotein(a) [Lp(a)] concentration in adults with high Lp(a) and no pre-existing cardiovascular disease. The trial was simultaneously published in the Journal of…
read more »
News from ACC.22 – Long-term data from HAUSER-OLE in paediatric familial hypercholesterolaemia
Results from the HAUSER Open-Label Extension Study (HAUSER-OLE) (1) show that treatment with evolocumab was well tolerated, safe, and led to substantial reduction in LDL cholesterol in children with heterozygous familial hypercholesterolaemia (FH). As previously reported on PCSK9 Forum, HAUSER-RCT evaluated the efficacy and safety…
read more »
News from ACC.22 late breaking trials: PACMAN-AMI delivers
Results from the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) trial using multimodality coronary imaging demonstrate the benefit of starting intensive lipid lowering in the acute setting of acute myocardial infarction (AMI). PCSK9 inhibition on top…
read more »
